<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CLOMIPRAMINE HYDROCHLORIDE</span><br/>(clo-mi'pra-meen)<br/><span class="topboxtradename">Anafranil<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">tricyclic antidepressant</span><br/><b>Prototype: </b>Imipramine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 75 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuron. Elevates serum levels of these two amines.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The basis of its antidepressant effects is thought to be due to the elevated serum levels of norepinephrine and serotonin.
         Exhibits anticholinergic, antihistaminic, hypotensive, sedative, mild analgesic, and peripheral vasodilator effects.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Obsessive-compulsive disorder (OCD).</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Panic disorder, anxiety, agoraphobia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to other tricyclic compounds; acute recovery period after MI, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of convulsive disorders, prostatic hypertrophy, urinary retention, cardiovascular, hepatic, GI, or blood disorders.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Obsessive-compulsive Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75300 mg/d in divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>1018 y:</i> 100200 mg/d in divided doses, start at 50 mg/d<br/><br/><span class="indicationtitle">Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50150 mg/d in single or divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give in divided doses with meals to reduce GI adverse effects.</li>
<li>Following titration to the full dose, drug may be given as a single dose at bedtime to reduce daytime sedation.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Diaphoresis. <span class="typehead">CV:</span> Hypotension, tachycardia. <span class="typehead">GI:</span> Constipation, <span class="speceff-common">dry mouth.</span>
<span class="typehead">Endocrine:</span> Galactorrhea, hyperprolactinemia, amenorrhea, <span class="speceff-common">weight gain.</span>
<span class="typehead">Hematologic:</span> Leukopenia, <span class="speceff-life">agranulocytosis</span>, thrombocytopenia, anemia. <span class="typehead">CNS:</span> Mania, <span class="speceff-common">tremor,</span> dizziness, hyperthermia, <span class="speceff-life">neuroleptic malignant syndrome</span>, seizures (especially with abrupt withdrawal). <span class="typehead">Urogenital:</span> Delayed ejaculation, anorgasmia. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Clomipramine appears to elevate serum <span class="alt">prolactin</span> levels. <span class="alt">Serum AST and ALT</span> are elevated. Serum levels of <span class="alt">triiodothyronine (T<sub>3</sub>) and free triiodothyronine (FT<sub>3</sub>)</span> have been significantly reduced from baseline. <span class="alt">Thyroxine-binding globulin (TBG)</span> levels were increased from baseline, whereas <span class="alt">thyroxine (T<sub>4</sub>),</span>
<span class="alt">free thyroxine (FT<sub>4</sub>),</span> and reverse <span class="alt">T<sub>3</sub>
</span> were unchanged.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">mao inhibitors</span> may precipitate hyperpyrexic crisis, tachycardia, or seizures; <span class="classification">antihypertensive agents</span> potentiate orthostatic hypotension; <span class="classification">cns depressants</span>, <b>alcohol</b> add to CNS depression; <b>norepinephrine</b> and other <span class="classification">sympathomimetics</span> may increase cardiac toxicity; <b>cimetidine</b> decreases hepatic metabolism, thus increasing imipramine levels; <b>methylphenidate</b> inhibits metabolism of <b>imipramine</b> and thus may increase its toxicity. <span class="typehead">Herbal:</span>
<b>Ginkgo</b> may decrease seizure threshold; <b>St. John's wort</b> may cause serotonin syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 2078% reaches systemic circulation. <span class="typehead">Onset:</span> Depression: approx 2 wk; OCD: approx 410 wk. <span class="typehead">Peak:</span> 26 h. <span class="typehead">Distribution:</span> Widely distributed including the CSF; crosses placenta. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism in the liver; active metabolite is desmethylclomipramine. <span class="typehead">Elimination:</span> 5060% excreted in urine, 2432% in feces. <span class="typehead">Half-Life:</span> 2030 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for seizures, especially in those with predisposing factors such as alcoholism, brain injury, or concurrent therapy
            with other drugs that lower seizure threshold.
         </li>
<li>Lab tests: Periodic CBC with differential, platelet count, and Hct and Hgb. Monitor liver functions, especially with long-term
            therapy.
         </li>
<li>Monitor for and report signs of neuroleptic malignant syndrome (see Appendix F).</li>
<li>Monitor for sedation and vertigo, especially at the beginning of therapy and following dosage increases. Supervision of ambulation
            may be indicated.
         </li>
<li>Notify physician of fever and complaints of sore throat since these may indicated need to rule out adverse hematologic changes.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take nonprescribed drugs or discontinue therapy without consent of physician. Abrupt discontinuation may cause nausea,
            headache, malaise, or seizures.
         </li>
<li>Men should understand that the drug may cause impotence or ejaculation failure. Advise them to report this problem to physician.</li>
<li>Report promptly a sore throat accompanied by fever.</li>
<li>Use caution with ambulation until response to drug is known.</li>
<li>Moderate alcohol intake since it may potentiate adverse drug effects.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>